FDA OKs Aralez Pharma's Yosprala; shares up 13%

• The FDA approves Aralez Pharmaceuticals' (NASDAQ:ARLZ-OLD +12.8%) YOSPRALA (aspirin + omeprazole) for the secondary prevention of cardiovascular and cerebrovascular events in patients at risk for aspirin-induced gastric ulcers. The company is expanding its salesforce to 110 from 25 as it prepares for the U.S. launch next month.
• YOSPRALA is a combination of omeprazole, a proton pump inhibitor that reduces stomach acid, and a PH-sensitive enteric coated aspirin.
• Management will host a conference call today at 11:00 am ET to discuss its plans.
• Update: Slingshot Insights has a proposed expert interview to discuss YOSPRALA's market potential.